Strike The Balance Between Cost-Effective And Risk-Averse Biologic Manufacturing
By Nigel Stapleton, VP of Business Development, Head of Europe; Adam Pietruszkiewicz, Chief Commercial Officer; and Marty Henehan, VP of Business Development, Head of North America

In the push to accommodate an increasingly global pharmaceutical market, drug sponsors are working to strike the ever-delicate balance between risk mitigation, speed to market, and high product quality. Though outsourcing to the Asia-Pacific region has long been a popular option for U.S. and European drug sponsors, recent geopolitical tensions and supply chain challenges are leading many to consider the benefits of partnering with a domestic or allied CDMO to manufacture their biologic.
While domestic and allied partnerships can help sponsors avoid risks to IP, supply chain delays, and potential tariffs, drug sponsors must be strategic to find capacity from said partners. To secure a manufacturing slot with a U.S. or European CDMO, it is important to start discussions with potential partners as early as possible. The sooner you find the right partner, the sooner your biologic will be on track to reaching patients.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.